GlassScriptPhysician profile
Dip Sureshkumar Jadav
NPI 1497908883
$3,699.91
in general payments reported to CMS, 2019-2025
28 companies · $547 in 2025
The $547 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,338 · 2020: $205 · 2021: $196 · 2022: $370 · 2023: $594 · 2024: $450 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,451 · Long Term Medical Supply Or Device Loan: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,451.27 |
| Long Term Medical Supply Or Device Loan | $140.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,201.31 | 2019-2025 | Clareon, Hydrus Microstent, Argos |
| Sun Pharmaceutical Industries INC. | $637.88 | 2019-2025 | Cequa |
| Abbvie INC. | $422.60 | 2022-2025 | |
| Ocular Therapeutix, INC. | $254.88 | 2023 | Dextenza |
| Biotissue Holdings INC. | $169.21 | 2021-2024 | |
| Glaukos Corporation | $160.75 | 2022-2025 | Idose, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Kala Pharmaceuticals, INC. | $74.87 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $74.42 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $68.86 | 2024-2025 | Xdemvy |
| Carl Zeiss Meditec, INC. | $67.84 | 2019 | |
| Thea Pharma INC. | $62.73 | 2023-2025 | Iyuzeh |
| Bausch & Lomb Americas INC. | $53.88 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sight Sciences, INC. | $50.12 | 2024 | Omni Surgical System |
| Allergan, INC. | $43.46 | 2022 | |
| Eyevance Pharmaceuticals LLC | $37.98 | 2019-2023 | Flarex |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $37.02 | 2024-2025 | Vevye |
| Omeros Corporation | $32.78 | 2019 | |
| Dompe US, INC. | $32.57 | 2025 | Oxervate |
| Oyster Point Pharma, INC. | $32.27 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $29.64 | 2021-2025 | Catalys System |
| Beaver-Visitec International, INC. | $27.39 | 2025 | |
| Carl Zeiss Meditec USA, INC. | $22.69 | 2024 | Cirrus Hd-Oct |
| Aerie Pharmaceuticals, INC. | $21.62 | 2019 | |
| Shire North American Group INC | $20.09 | 2019 | |
| New World Medical,INC. | $18.50 | 2025 | Ahmed Glaucoma Valve, Via360, Clearpath |
| Amgen INC. | $16.63 | 2025 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $15.14 | 2019 | |
| Mallinckrodt Enterprises LLC | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dip Jadav listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.